Articles > Devices & Technology

We're going to take the opportunity to share out some critical resources each week that may help people get through this challenging coronavirus pandemic with the help of partners and experts.

The COVID-19 pandemic has put immense pressure on both individuals with T1D, and the organizations who provide them with vital supplies and medications. While there’s no doubt that people with T1D face a more uncertain and risk-filled future as we navigate quarantine and social distancing, there have been some promising steps from several sides that have …

the liver can be just as important as the pancreas in treating type 1 diabetes

Diasome Pharmaceuticals announced positive results this week from a Phase 2 study of its injectable hepatocyte directed vesicle (HDV) additive for insulin in patients with type 1 diabetes. The news could prove a major step forward for therapies that aim to improve and optimize the way insulin is used and metabolized by the body. In …

Woman showing another woman data on her smartphone about health and exercise.

The T1D Exchange Registry launched last year, and it’s begun to provide a fascinating and vital look into some of the more detailed aspects of life with type 1 diabetes. From your age of diagnosis to frequency of testing, we’ve learned more about how you’re living, working, and caring for diabetes across the country.

Data security is paramount for health registry databases

Today, January 28th, has been designated by the Council of Europe as Data Privacy and Protection Day since 2007, and recognized two years later by the U.S. Congress in 2009.

Executives of the Big Three pharma companies involved in diabetes research, development, and manufacturing — Eli Lilly and Co., Novo Nordisk, and Sanofi — spoke publicly this week at JPMorgan’s 2020 Healthcare conference on issues related to insulin pricing and supply.

Tandem t:slim X 2 pump with control IQ technology

Last month, the FDA approved the Tandem Diabetes Care update to its t:slim X2 insulin pump Control-IQ technology, clearing the way for the first automated and interoperable insulin dosing system on the U.S. market.

logo for French pharma manufacturer Sanofi

Sanofi, the French pharmaceutical giant which manufactures the long-acting insulin Lantus, announced Monday that it would no longer be investing in research for new drugs to treat diabetes. The manufacturer also told investors it would no longer be investigating new treatments for cardiovascular health. “To be out of cardiovascular and diabetes is not easy for …

Two airline pilots monitoring instruments

The FAA is moving to allow pilots with type 1 diabetes to take command of U.S.-based commercial flights, reports CNN.

Tandem Insulin pump

A new study published in the New England Journal of Medicine (NEJM) showed promising results for closed-loop insulin delivery systems, the journal and participating manufacturers reported last week.